Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Cash & Equivalents (2016 - 2025)

Sangamo Therapeutics has reported Cash & Equivalents over the past 16 years, most recently at $20.9 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $20.9 million for Q4 2025, down 50.03% from a year ago — trailing twelve months through Dec 2025 was $20.9 million (down 50.03% YoY), and the annual figure for FY2025 was $20.9 million, down 50.03%.
  • Cash & Equivalents for Q4 2025 was $20.9 million at Sangamo Therapeutics, down from $29.6 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for SGMO hit a ceiling of $178.9 million in Q4 2021 and a floor of $20.9 million in Q4 2025.
  • Median Cash & Equivalents over the past 5 years was $61.7 million (2023), compared with a mean of $80.3 million.
  • Peak annual rise in Cash & Equivalents hit 43.41% in 2021, while the deepest fall reached 63.66% in 2021.
  • Sangamo Therapeutics' Cash & Equivalents stood at $178.9 million in 2021, then plummeted by 43.85% to $100.4 million in 2022, then tumbled by 55.0% to $45.2 million in 2023, then fell by 7.27% to $41.9 million in 2024, then plummeted by 50.03% to $20.9 million in 2025.
  • The last three reported values for Cash & Equivalents were $20.9 million (Q4 2025), $29.6 million (Q3 2025), and $38.3 million (Q2 2025) per Business Quant data.